

# Atanasio Pandiella

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4648007/atanasio-pandiella-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217  
papers

9,007  
citations

50  
h-index

85  
g-index

225  
ext. papers

10,025  
ext. citations

6.8  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
217	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 106	12.8	0
216	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5476	6.3	1
215	Transcriptomic Mapping of Non-Small Cell Lung Cancer p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 786069	8.4	1
214	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 144, 112330	7.5	0
213	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 313	12.8	2
212	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 106	12.8	4
211	PDCD4 limits prooncogenic neuregulin-ErbB signaling. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 1799-1815	10.3	2
210	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. <i>Cellular Oncology (Dordrecht)</i> , <b>2021</b> , 44, 569-580	7.2	5
209	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
208	Ocoxin oral solution demonstrates antiviral properties in cellular models. <i>Experimental and Therapeutic Medicine</i> , <b>2021</b> , 22, 1127	2.1	
207	Altered proTGF $\beta$ cleaved TGF $\beta$ ratios offer new therapeutic strategies in renal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 256	12.8	0
206	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 78	9.8	4
205	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5096-5108	12.9	2
204	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	5
203	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 3117-3127	5.6	6
202	Integrin $\beta$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , <b>2020</b> , 24, 143-151	4.5	3
201	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , <b>2020</b> , 6, 130-146	12.5	26

200	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11498	12	18
199	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 15	8.3	18
198	Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. <i>Cancer Letters</i> , <b>2020</b> , 470, 161-169	9.9	7
197	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
196	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. <i>Cancer Letters</i> , <b>2020</b> , 491, 50-59	9.9	5
195	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	26
194	Proteolysis targeting chimeras (PROTACs) in cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 189	12.8	20
193	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
192	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 383	12.8	32
191	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 77, 11-19	14.4	11
190	Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	4
189	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , <b>2019</b> , 14, e0209134	3.7	8
188	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. <i>Cancer Letters</i> , <b>2019</b> , 453, 34-44	9.9	9
187	Mapping Bromodomains in breast cancer and association with clinical outcome. <i>Scientific Reports</i> , <b>2019</b> , 9, 5734	4.9	5
186	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1486	5.3	15
185	Screening and Preliminary Biochemical and Biological Studies of [RuCl(-cymene)(,-bis(diphenylphosphino)-isopropylamine)][BF] in Breast Cancer Models. <i>ACS Omega</i> , <b>2019</b> , 4, 13005-13014	3.9	2
184	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1629780	7.2	12
183	Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. <i>Nanomaterials</i> , <b>2019</b> , 9,	5.4	6

182	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1040	5.3	22
181	Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA-MB 231 breast cancer cells. <i>Molecular Medicine Reports</i> , <b>2019</b> , 20, 73-80	2.9	2
180	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2802	8.4	13
179	MEK5 promotes lung adenocarcinoma. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	5
178	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 693-701	4.4	18
177	The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1061-1076	7.9	4
176	Resistance to Antibody-Drug Conjugates. <i>Cancer Research</i> , <b>2018</b> , 78, 2159-2165	10.1	85
175	Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , <b>2018</b> , 7, 1896-1907	4.8	10
174	Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer. <i>International Journal of Oncology</i> , <b>2018</b> , 53, 113-123	4.4	8
173	Colorectal cancer and medicinal plants: Principle findings from recent studies. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 107, 408-423	7.5	36
172	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207776	3.7	4
171	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , <b>2018</b> , 39, 922-925	13.2	11
170	Transcriptome evolution from breast epithelial cells to basal-like tumors. <i>Oncotarget</i> , <b>2018</b> , 9, 453-463	3.3	9
169	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , <b>2018</b> , 9, 31915-31919	3.3	12
168	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 725-732	4.4	7
167	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 337-343	4.5	3
166	Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1788-1805	7.9	5
165	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , <b>2017</b> , 8, 73144-73153	3.3	19

164	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7006-7019	12.9	41
163	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2552-2562	6.1	32
162	Antitumoral effect of Ocoxin in hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2017</b> , 14, 1950-1958	2.6	10
161	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , <b>2017</b> , 7, 17530	4.9	41
160	Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. <i>Cancer Research</i> , <b>2017</b> , 77, 4639-4651	10.1	72
159	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. <i>Oncogene</i> , <b>2017</b> , 36, 1733-1744	9.2	28
158	Neutrophils in cancer: prognostic role and therapeutic strategies. <i>Molecular Cancer</i> , <b>2017</b> , 16, 137	42.1	169
157	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175128	3.7	20
156	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 62834-62841	3.3	11
155	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 29679-29698	3.3	8
154	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. <i>Oncotarget</i> , <b>2017</b> , 8, 19478-19490	3.3	22
153	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , <b>2017</b> , 8, 22218-22234	3.3	33
152	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , <b>2017</b> , 8, 21733-21740	3.3	13
151	BET inhibitors as novel therapeutic agents in breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 71285-71291	3.3	27
150	Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. <i>Current Cancer Drug Targets</i> , <b>2017</b> , 17, 48-52	2.8	2
149	Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of <i>Aristolochia longa</i> L.. <i>International Journal of Pharmaceutical and Phytopharmacological Research</i> , <b>2017</b> , 6, 20		7
148	Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e17089-e17089	2.2	
147	Modulation of cereblon levels by anti-myeloma agents. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 167-76	1.9	6

146	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1823-33	6.1	20
145	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 1-8	4.4	8
144	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 399-406	4	25
143	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. <i>Oncogene</i> , <b>2016</b> , 35, 2756-65	9.2	16
142	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154789	3.7	23
141	Multisite phosphorylation of P-Rex1 by protein kinase C. <i>Oncotarget</i> , <b>2016</b> , 7, 77937-77949	3.3	6
140	In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , <b>2016</b> , 7, 22865-72	3.3	17
139	Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies. <i>Oncotarget</i> , <b>2016</b> , 7, 45042-45051	3.3	14
138	Targeting the EGF/HER Ligand-Receptor System in Cancer. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 5887-5898	3.5	35
137	Antitumoral effect of Ocoxin on acute myeloid leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 6231-42	3.3	17
136	Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester. <i>International Journal of Toxicology</i> , <b>2016</b> , 35, 666-671	2.4	6
135	Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer. <i>Nutrition and Cancer</i> , <b>2015</b> , 67, 1159-69	2.8	17
134	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. <i>Gut</i> , <b>2015</b> , 64, 1454-65	19.2	45
133	Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1298-9	2.2	25
132	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , <b>2015</b> , 29, 705-14	10.7	50
131	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 27923-37	3.3	19
130	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. <i>Oncotarget</i> , <b>2015</b> , 6, 30057-71	3.3	13
129	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. <i>Oncotarget</i> , <b>2015</b> , 6, 31272-83	3.3	6

128	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. <i>Oncotarget</i> , <b>2015</b> , 6, 32856-67	3.3	15
127	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , <b>2015</b> , 6, 39538-49	3.3	23
126	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 1048-55	14.4	27
125	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. <i>BMC Cancer</i> , <b>2014</b> , 14, 302	4.8	37
124	NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4014-25	12.9	37
123	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. <i>Oncogene</i> , <b>2014</b> , 33, 148-56	9.2	67
122	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e95219	3.7	119
121	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 115-6	0.8	
120	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	30
119	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 308	5.3	15
118	Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 504-16	6.1	7
117	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 295-307	9.6	3
116	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , <b>2014</b> , 5, 8284-305	3.3	37
115	Therapeutic potential of ERK5 targeting in triple negative breast cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11308-18	3.3	35
114	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 763-4	0.8	2
113	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 763-764	0.8	2
112	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 235-46	7.5	14
111	ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. <i>Neoplasia</i> , <b>2013</b> , 15, 649-59	6.4	30

110	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , <b>2013</b> , 27, 430-40	10.7	98
109	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 200-5	4.3	10
108	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. <i>Cellular Signalling</i> , <b>2013</b> , 25, 2281-9	4.9	14
107	A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. <i>Oncogene</i> , <b>2013</b> , 32, 1452-9	9.2	8
106	The evolving landscape of protein kinases in breast cancer: clinical implications. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 68-76	14.4	19
105	Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. <i>Stem Cells</i> , <b>2013</b> , 31, 1075-85	5.8	67
104	Molecular pathways: P-Rex in cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4564-9	12.9	20
103	HER3 overexpression and survival in solid tumors: a meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 266-73	9.7	141
102	Potent antimyeloma activity of a novel ERK5/CDK inhibitor. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2677-87	12.9	38
101	Targeting HER receptors in cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 808-17	3.3	32
100	Elapachone analogs with enhanced antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 53, 264-74	6.8	29
99	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. <i>International Journal of Oncology</i> , <b>2012</b> , 41, 1128-38	4.4	43
98	Sox2 expression in breast tumours and activation in breast cancer stem cells. <i>Oncogene</i> , <b>2012</b> , 31, 1354-65	9.2	383
97	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , <b>2012</b> , 26, 1862-9	10.7	54
96	Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. <i>PLoS ONE</i> , <b>2012</b> , 7, e34914	3.7	51
95	Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 244-52	7.5	34
94	Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1342-52	6.1	38
93	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , <b>2012</b> , 97, 1110-4	6.6	30



92	Deficient spindle assembly checkpoint in multiple myeloma. <i>PLoS ONE</i> , <b>2011</b> , 6, e27583	3.7	31
91	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. <i>Oncogene</i> , <b>2011</b> , 30, 1059-71	9.2	76
90	A modular approach to trim cellular targets in anticancer drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 6641-5	2.9	6
89	Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 311-8	4.4	28
88	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , <b>2011</b> , 96, 687-95	6.6	11
87	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2543-9	2.2	52
86	Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5546-52	12.9	204
85	Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 24350-63	5.4	3
84	Multisite phosphorylation of Erk5 in mitosis. <i>Journal of Cell Science</i> , <b>2010</b> , 123, 3146-56	5.3	41
83	Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4382-91	12.9	45
82	Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1432-46	9.7	39
81	Do we have to change the way targeted drugs are developed?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e420-1; author reply e422-3	2.2	11
80	Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 3835-9	8.3	17
79	Personalized therapies in the cancer "omics" era. <i>Molecular Cancer</i> , <b>2010</b> , 9, 202	42.1	39
78	Preclinical development of molecular-targeted agents for cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 8, 200-9	19.4	116
77	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , <b>2010</b> , 95, 794-803	6.6	133
76	Enhancement of antiproliferative activity by molecular simplification of catalpol. <i>Bioorganic and Medicinal Chemistry</i> , <b>2010</b> , 18, 2515-23	3.4	16
75	Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. <i>Leukemia Research</i> , <b>2010</b> , 34, 1533-8	2.7	20

74	Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. <i>PLoS ONE</i> , <b>2009</b> , 4, e5565	3.7	76
73	ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. <i>PLoS ONE</i> , <b>2009</b> , 4, e6124	3.7	35
72	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , <b>2009</b> , 23, 2265-74	10.7	51
71	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. <i>Leukemia</i> , <b>2009</b> , 23, 1515-27	10.7	113
70	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , <b>2009</b> , 113, 3781-91	2.2	66
69	Novel tyrosine kinase inhibitors in the treatment of cancer. <i>Current Drug Targets</i> , <b>2009</b> , 10, 575-6	3	16
68	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 470-82	4.5	33
67	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , <b>2008</b> , 9, 1157-65	21.7	106
66	Neuregulins and cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3237-41	12.9	81
65	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , <b>2008</b> , 93, 57-66	6.6	50
64	Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 961-70	12.9	36
63	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1860-9	10.3	49
62	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 3403-11	4.3	22
61	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. <i>Cancer Research</i> , <b>2008</b> , 68, 5216-25	10.1	79
60	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. <i>Molecular and Cellular Biology</i> , <b>2008</b> , 28, 5605-20	4.8	137
59	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. <i>Haematologica</i> , <b>2008</b> , 93, 851-9	6.6	26
58	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , <b>2007</b> , 21, 797-804	10.7	25
57	Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. <i>Cellular Signalling</i> , <b>2007</b> , 19, 844-54	4.9	36

56	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1473-87	4.9	24
55	Erk5 is activated and acts as a survival factor in mitosis. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1964-72	4.9	26
54	Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2656-63	2.2	51
53	The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. <i>Molecular Biology of the Cell</i> , <b>2007</b> , 18, 380-93	3.5	22
52	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18, 421-30	10.3	36
51	Antimyeloma Efficacy of Plitidepsin (Aplidin <sup>®</sup> ): From Bench to the Bedside.. <i>Blood</i> , <b>2007</b> , 110, 1178-1178	2	2
50	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.. <i>Blood</i> , <b>2007</b> , 110, 1515-1515	2.2	2
49	Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. <i>Cellular Physiology and Biochemistry</i> , <b>2006</b> , 18, 135-42	3.9	58
48	ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. <i>Journal of Immunology</i> , <b>2006</b> , 177, 7607-17	5.3	57
47	The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. <i>Cancer Research</i> , <b>2006</b> , 66, 5781-9	10.1	210
46	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , <b>2006</b> , 107, 3575-83	2.2	180
45	Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2006</b> , 29, 90-5	2.7	28
44	Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. <i>Journal of Pathology</i> , <b>2006</b> , 208, 108-18	9.4	50
43	TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. <i>Kidney International</i> , <b>2006</b> , 70, 901-9	9.9	66
42	Multifunctional role of Erk5 in multiple myeloma. <i>Blood</i> , <b>2005</b> , 105, 4492-9	2.2	70
41	N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. <i>Biochemical Journal</i> , <b>2005</b> , 389, 161-72	3.8	17
40	Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 665-7	7.5	52
39	Genetic abnormalities and patterns of antigenic expression in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3661-7	12.9	89

38	Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. <i>Cancer Research</i> , <b>2005</b> , 65, 6801-10	10.1	59
37	Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. <i>Journal of Biochemistry</i> , <b>2005</b> , 137, 731-9	3.1	3
36	Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. <i>Cellular Physiology and Biochemistry</i> , <b>2004</b> , 14, 301-10	3.9	42
35	A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 1387-98	5.9	33
34	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 858-68	4.5	43
33	Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 25933-9	5.4	41
32	A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. <i>Journal of Immunological Methods</i> , <b>2002</b> , 264, 77-87	2.5	27
31	Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 270-85	4.8	144
30	Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. <i>Molecular Biology of the Cell</i> , <b>2002</b> , 13, 2031-44	3.5	251
29	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , <b>2002</b> , 363, 211-21	3.8	37
28	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , <b>2002</b> , 363, 211-221	3.8	47
27	Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. <i>FEBS Letters</i> , <b>2002</b> , 513, 282-8	3.8	52
26	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , <b>2000</b> , 346, 359	3.8	18
25	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , <b>2000</b> , 346, 359-367	3.8	57
24	Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. <i>Molecular and Cellular Neurosciences</i> , <b>2000</b> , 16, 631-48	4.8	147
23	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. <i>European Journal of Neuroscience</i> , <b>1999</b> , 11, 1421-30	3.5	41
22	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , <b>1999</b> , 344, 339-348	3.8	19
21	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , <b>1999</b> , 344, 339	3.8	8

20	TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. <i>Journal of Cell Biology</i> , <b>1996</b> , 132, 427-36	7.3	94
19	Autocrine regulation of membrane transforming growth factor-alpha cleavage. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 3279-84	5.4	61
18	Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. <i>Experimental Cell Research</i> , <b>1993</b> , 205, 365-73	4.2	21
17	Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 1327-33	9.7	323
16	Membrane-anchored growth factors. <i>Annual Review of Biochemistry</i> , <b>1993</b> , 62, 515-41	29.1	593
15	Activated release of membrane-anchored TGF-alpha in the absence of cytosol. <i>Journal of Cell Biology</i> , <b>1993</b> , 122, 95-101	7.3	59
14	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF alpha into soluble growth factor. <i>Cell</i> , <b>1992</b> , 71, 1157-65	56.2	131
13	Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors. <i>Cellular Physiology and Biochemistry</i> , <b>1992</b> , 2, 196-212	3.9	2
12	Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 1726-30	11.5	208
11	Transforming growth factor-alpha. <i>Biochemical Society Transactions</i> , <b>1991</b> , 19, 259-62	5.1	11
10	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. <i>Journal of Neuroendocrinology</i> , <b>1991</b> , 3, 51-6	3.8	2
9	Voltage-operated calcium-channel subtypes in human neuroblastoma and rat pheochromocytoma cells. <i>Annals of the New York Academy of Sciences</i> , <b>1989</b> , 560, 249-50	6.5	1
8	Plasma membrane hyperpolarization and $[Ca^{2+}]_i$ increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: resemblance to early signals generated by platelet-derived growth factor. <i>Biochemical and Biophysical Research Communications</i> , <b>1989</b> , 163, 1325-31	3.4	35
7	Intracellular calcium homeostasis in a human neuroblastoma cell line: modulation by depolarization, cholinergic receptors, and alpha-latrotoxin. <i>Journal of Neurochemistry</i> , <b>1988</b> , 50, 1708-13 <sup>6</sup>		25
6	Omega-conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines. <i>FEBS Letters</i> , <b>1988</b> , 235, 178-82	3.8	74
5	Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free $Ca^{2+}$ in rat somatotrophs. <i>Endocrinology</i> , <b>1988</b> , 122, 1419-25	4.8	20
4	EGF raises cytosolic $Ca^{2+}$ in A431 and Swiss 3T3 cells by a dual mechanism. Redistribution from intracellular stores and stimulated influx. <i>Experimental Cell Research</i> , <b>1987</b> , 170, 175-85	4.2	86
3	Protein kinase C-mediated feed back inhibition of the $Ca^{2+}$ response at the EGF receptor. <i>Biochemical and Biophysical Research Communications</i> , <b>1987</b> , 149, 145-51	3.4	22

- 2 PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. *Biochemical and Biophysical Research Communications*, **1986**, 137, 343-50 3.4 47
- 1 Early rise of cytosolic Ca<sup>2+</sup> induced by NGF in PC12 and chromaffin cells. *FEBS Letters*, **1986**, 208, 48-51 3.8 82